Aligos Therapeutics ALGS 深 沪
等待开盘 12-20 09:30:00 美东时间
10.52
+0.150
+1.45%
华盛通- 最 高11.0445
- 今 开10.32
- 成交量 4.87万股
- 最 低 10.32
- 昨 收 10.37
- 总市值 6432.77万
- 52周最高 46.80
- 市盈率 静 --
- 换手率 0.80%
- 52周最低 3.76
- 委 比 11.11%
- 总股本 611.48万
- 历史最高 937.75
- 量 比 0.43
- 振 幅 6.99%
- 历史最低 3.76
- 每 手 1
- 风险率 9.44%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Athira Pharma (NASDAQ:ATHA) stock increased by 30.6% to $5.4 during Th...
12-18 20:05
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aligos Therapeutics granted 14,100 non-qualified stock options to newly hired employees under its 2024 Inducement Plan on December 9, 2025. The options have an exercise price equal to the closing stock price on the grant date and vest over four years, with 25% vesting after the first year and the rest in monthly installments. The company, focused on developing therapies for liver and viral diseases, uses the plan exclusively for new hires not pre...
12-12 13:00
Aligos Therapeutics Announces Data From Four Presentations, Including Two Oral Presentations, At HEP-DART 2025 Meeting
Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from
12-11 21:11
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aligos Therapeutics granted 23,600 non-qualified stock options to newly hired employees on November 11, 2025, under its 2024 Inducement Plan. The options have an exercise price based on the stock's closing price on the grant date and vest over four years, with 25% vesting after the first year and the remainder vesting monthly. Aligos, a clinical-stage biopharmaceutical company, focuses on developing therapies for liver and viral diseases.
11-14 13:00
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025
Aligos Therapeutics announced positive data for pevifoscorvir sodium at the AASLD 2025 meeting, highlighting its best-in-class potential for treating chronic hepatitis B. The oral and poster presentations showed sustained viral suppression, with 75% of HBeAg+ and 100% of HBeAg- subjects maintaining HBV DNA below the lower limit of quantification during NA monotherapy. Pevifoscorvir sodium's ability to reduce HBV antigen and RNA levels, along with...
11-10 13:00
Aligos Therapeutics shares are trading lower after the company reported worse-than-expected Q3 EPS results.
Aligos Therapeutics shares are trading lower after the company reported worse-t...
11-06 23:59
Aligos Therapeutics Q3 EPS $(3.04) Misses $(2.27) Estimate, Sales $741.000K Beat $500.000K Estimate
Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(3.04) per share which missed the analyst consensus estimate of $(2.27) by 34.22 percent. This is a 0.98 percent increase over losses of $(3.07) per share
11-06 21:31
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Aligos Therapeutics to Present at Upcoming Investor Conferences
Aligos Therapeutics announced that its management will participate in two upcoming investor conferences: the Jefferies London Healthcare Conference on November 17, 2025, and the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025. Both events will feature fireside chats, which can be accessed via Aligos’ website.
11-04 13:30
Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025
Aligos Therapeutics announced it will release its Q3 2025 financial results on November 6, 2025. The clinical-stage biotech company focuses on developing best-in-class therapies for liver and viral diseases, addressing high unmet medical needs like chronic hepatitis B, obesity, and coronaviruses. For more details, visit www.aligos.com.
10-30 12:30
